Drug General Information |
Drug ID |
D0W3LI
|
Former ID |
DNC000906
|
Drug Name |
LY333531
|
Drug Type |
Small molecular drug
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 2 |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C28H28N4O3
|
Canonical SMILES |
CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C<br />65)C(=O)NC4=O
|
InChI |
1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
|
InChIKey |
ZCBUQCWBWNUWSU-SFHVURJKSA-N
|
CAS Number |
CAS 169939-94-0
|
PubChem Compound ID |
|
PubChem Substance ID |
833541, 10251931, 10318977, 14760780, 14760781, 46230219, 46393342, 46517285, 50070524, 50071162, 50100106, 50462855, 57347953, 85267527, 103298456, 104020046, 104437748, 126665974, 129881271, 134223871, 134339404, 134339800, 134340199, 134340298, 135109631, 137249719, 137266253, 142787245, 178101947, 179150054, 198935331, 223661453, 228602703
|
Target and Pathway |
Target(s) |
Protein kinase C, beta type |
Target Info |
Inhibitor |
[2],
[3],
[4]
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Chemokine signaling pathway
|
NF-kappa B signaling pathway
|
HIF-1 signaling pathway
|
Phosphatidylinositol signaling system
|
Sphingolipid signaling pathway
|
mTOR signaling pathway
|
Vascular smooth muscle contraction
|
Wnt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Tight junction
|
Gap junction
|
Natural killer cell mediated cytotoxicity
|
B cell receptor signaling pathway
|
Fc epsilon RI signaling pathway
|
Fc gamma R-mediated phagocytosis
|
Leukocyte transendothelial migration
|
Circadian entrainment
|
Long-term potentiation
|
Retrograde endocannabinoid signaling
|
Glutamatergic synapse
|
Cholinergic synapse
|
Serotonergic synapse
|
GABAergic synapse
|
Dopaminergic synapse
|
Long-term depression
|
Inflammatory mediator regulation of TRP channels
|
Insulin secretion
|
GnRH signaling pathway
|
Melanogenesis
|
Thyroid hormone synthesis
|
Thyroid hormone signaling pathway
|
Oxytocin signaling pathway
|
Aldosterone-regulated sodium reabsorption
|
Endocrine and other factor-regulated calcium reabsorption
|
Salivary secretion
|
Gastric acid secretion
|
Pancreatic secretion
|
Carbohydrate digestion and absorption
|
Amphetamine addiction
|
Morphine addiction
|
Vibrio cholerae infection
|
Leishmaniasis
|
African trypanosomiasis
|
Amoebiasis
|
Hepatitis B
|
Influenza A
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Glioma
|
Non-small cell lung cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
Angiogenesis
|
Apoptosis signaling pathway
|
B cell activation
|
EGF receptor signaling pathway
|
Endothelin signaling pathway
|
FGF signaling pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Metabotropic glutamate receptor group I pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
VEGF signaling pathway
|
Wnt signaling pathway
|
5HT2 type receptor mediated signaling pathway
|
Histamine H1 receptor mediated signaling pathway
|
Oxytocin receptor mediated signaling pathway
|
Thyrotropin-releasing hormone receptor signaling pathway
|
CCKR signaling map ST
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
TCR signaling in naï
|
TCR signaling in naï
|
IL2-mediated signaling events
|
Ras signaling in the CD4+ TCR pathway
|
JNK signaling in the CD4+ TCR pathway
|
Regulation of Ras family activation
|
Downstream signaling in naï
|
Reactome
|
Disinhibition of SNARE formation
|
Activation of NF-kappaB in B cells
|
Trafficking of GluR2-containing AMPA receptors
|
G alpha (z) signalling events
|
Depolymerisation of the Nuclear Lamina
|
WNT5A-dependent internalization of FZD4
|
VEGFR2 mediated cell proliferation
|
Response to elevated platelet cytosolic Ca2+
|
WikiPathways
|
Calcium Regulation in the Cardiac Cell
|
Insulin Signaling
|
EGF/EGFR Signaling Pathway
|
Wnt Signaling Pathway
|
Wnt Signaling Pathway and Pluripotency
|
MAPK Signaling Pathway
|
Wnt Signaling Pathway Netpath
|
G Protein Signaling Pathways
|
Kit receptor signaling pathway
|
Myometrial Relaxation and Contraction Pathways
|
Signaling by the B Cell Receptor (BCR)
|
Oncostatin M Signaling Pathway
|
Corticotropin-releasing hormone
|
AGE/RAGE pathway
|
B Cell Receptor Signaling Pathway
|
Signaling Pathways in Glioblastoma
|
miRs in Muscle Cell Differentiation
|
Response to elevated platelet cytosolic Ca2+
|
MicroRNAs in cardiomyocyte hypertrophy
|
Physiological and Pathological Hypertrophy of the Heart
|
References |
REF 1 | ClinicalTrials.gov (NCT00482976) Effect of LY333531 on Vascular and Neural Functions. U.S. National Institutes of Health. |
---|
REF 2 | Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med. 2000;5(3):173-85. |
---|
REF 3 | Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8. |
---|
REF 4 | Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997 Jul 1;100(1):115-26. |